Haleon
HLN | NYSE
$9.36
+$0.08 (+0.86%)
At close: Sep 21, 2026, 4:00 PM ET
$9.38
+$0.02 (+0.21%)
After-hours:
Sep 21, 2026, 4:31 PM ET
Company Profile
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Key Executives
| Name | Position |
|---|---|
| Brian James McNamara | Chief Executive Officer & Executive Director |
| Dawn Amanda Allen | Chief Financial Officer & Director |
| Tamara Rogers | Chief Marketing Officer |
| Adrian Charles Morris | General Counsel |
| Bjorn Timelin | Head of Strategy |
| Claire Dickson | Chief Digital & Technology Officer |
| Filippo Lanzi | President of EMEA & LatAm |
| Joanne Russell | Head of Investor Relations |
| Keith Choy | President of Asia Pacific |
| Line De Decker | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 01, 2026 | 6-K | Filing |
| Aug 26, 2026 | CERT | Filing |
| Aug 21, 2026 | 8-A12B | Filing |
| Aug 21, 2026 | 6-K | Filing |
| Aug 19, 2026 | 6-K | Filing |
| Aug 19, 2026 | 6-K | Filing |
| Aug 17, 2026 | 6-K | Filing |
| Aug 13, 2026 | 424B5 | Filing |
| Aug 13, 2026 | 6-K | Filing |
| Aug 13, 2026 | FWP | Filing |
Haleon
| Country | United Kingdom |
| IPO Date | Jul 24, 2022 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 24,535 |
| CEO | Brian James McNamara |
Contact Details
The Heights Weybridge,
SU KT13 0NY United Kingdom
Stock Details
| Ticker Symbol | HLN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001900304 |
| CUSIP Number | 405552100 |
| ISIN Number | US4055521003 |
| SIC Code | 2844 |
Recent News
- 5 days ago / reuters.comAdvil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs
- 19 days ago / reuters.comHaleon secures better shelf space at Walmart, Target in bid to boost market share
- 29 days ago / proactiveinvestors.co.ukJefferies raises Haleon price target to 410p on margin strength
- 1 month ago / prnewswire.comHaleon plc: Announces Pricing Terms, Expiration and Results of its Cash Tender Offer for outstanding 2027 Notes
- 1 month ago / prnewswire.comHaleon plc: Cash tender offer for outstanding 2027 3.375% Fixed Rate Notes
- 2 months ago / seekingalpha.comHaleon plc (HLN) Q2 2026 Earnings Call Prepared Remarks Transcript
- 2 months ago / seekingalpha.comHaleon plc (HLN) Q2 2026 Earnings Call Transcript
- 3 months ago / benzinga.comHaleon Bets on Microsoft AI To Support Growth and Reach One Billion More Consumers by 2030
- 3 months ago / businesswire.comHaleon to Accelerate AI-powered Transformation With New Five-year Microsoft Collaboration
- 4 months ago / businesswire.comHaleon Issues Voluntary Nationwide Recall of Gas-X Extra Strength Softgels 125mg, 120 ct. and 72 ct.
Add to Watchlist
Select watchlists to add or remove HLN